Changes in the expression and dynamics of SHP-1 and SHP-2 during cerulein-induced acute pancreatitis in rats.
Protein tyrosine phosphatases (PTPs) are important regulators of cell functions but data on different PTP expression and dynamics in acute pancreatitis (AP) are very scarce. Additionally, both c-Jun N-terminal kinases (JNK) and extracellular signal-regulated kinases (ERK1/2), together with intracellular cAMP levels in inflammatory cells, play an essential role in AP. In this study we have detected an increase in PTP SHP-1 and SHP-2 in the pancreas at the level of both protein and mRNA as an early event during the development of Cerulein (Cer)-induced AP in rats. Nevertheless, while SHP-2 protein returned to baseline levels in the intermediate or later phases of AP, SHP-1 protein expression remained increased throughout the development of the disease. The increase in SHP-2 protein expression was associated with changes in its subcellular distribution, with higher percentages located in the fractions enriched in lysosomes+mitochondria or microsomes. Furthermore, while the increase in SHP-2 protein was also observed in sodium-taurocholate duct infusion or bile-pancreatic duct obstruction AP, that of SHP-1 was specific to the Cer-induced model. Neutrophil infiltration did not affect the increase in SHP-1 protein, but favoured the return of SHP-2 protein to control levels, as indicated when rats were rendered neutropenic by the administration of vinblastine sulfate. Inhibition of JNK and ERK1/2 with SP600125 pre-treatment further increased the expression of both SHP-1 and SHP-2 proteins in the early phase of Cer-induced AP, while the inhibition of type IV phosphodiesterase with rolipram only suppressed the increase in SHP-2 protein expression during the same phase. Our results show that AP is associated with increases in the expression of SHP-1 and SHP-2 and changes in the dynamics of SHP-2 subcellular distribution in the early phase of Cer-induced AP. Finally, both JNK and ERK1/2 and intracellular cAMP levels are able to modulate the expression of these PTPs.
Sarmiento
Nancy
N
Department of Biochemistry and Molecular Biology, University of Salamanca, Spain.
Sánchez-Bernal
Carmen
C
Ayra
Manuel
M
Pérez
Nieves
N
Hernández-Hernández
Angel
A
Calvo
José J
JJ
Sánchez-Yagüe
Jesús
J
D000818:Animals; D000873:Anthracenes / Q000494:pharmacology; D002108:Ceruletide; D048670:MAP Kinase Kinase 4 / Q000037:antagonists & inhibitors; D008297:Male; D048052:Mitogen-Activated Protein Kinase 3 / Q000037:antagonists & inhibitors; D009504:Neutrophils / Q000276:immunology; D010195:Pancreatitis / Q000139:chemically induced* / Q000201:enzymology*; D058988:Phosphodiesterase 4 Inhibitors; D053824:Protein Tyrosine Phosphatase, Non-Receptor Type 6 / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar; D020889:Rolipram / Q000494:pharmacology
D000873:Anthracenes; D058988:Phosphodiesterase 4 Inhibitors; C432165:pyrazolanthrone; D002108:Ceruletide; D048052:Mitogen-Activated Protein Kinase 3; D048670:MAP Kinase Kinase 4; D053824:Protein Tyrosine Phosphatase, Non-Receptor Type 6; D020889:Rolipram